CClinicalTrials.gg
CompletedNCT06690424Updated Apr 6, 2026

Clinical Studies of the Efficacy and Safety of Remimazolam for Anesthesia Induction and Maintenance in Elderly Patients

A Phase 4 interventional study of Remimazolam and Propofol in Efficacy and Safety, sponsored by Affiliated Hospital of Nantong University. Completed at 1 site in China. Open to participants aged 60 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-04-06.

Sponsored by Affiliated Hospital of Nantong University · Phase 4, Interventional, and Treatment

Phase
Phase 4
Study type
Interventional
Enrollment
92
Allocation
Randomized
Ages
60 Years to 75 Years
Sex
All
01

Study summary

the investigators are conducting a clinical study on the efficacy and safety of remimazolam for induction and maintenance of anesthesia in elderly patients. Project number: CRCF-YXFN-202401029, funded by the Red Cross Foundation of China and will take more than 2 years to complete.

This is a single-center, randomized, controlled clinical study, randomized 60 elderly subjects undergoing general anesthesia for elective surgery. According to the random number method, propofol group (control group, group P) and remimazolam group (experimental group, group R), 30 cases in each group.

By participating in this study, it is possible to make anesthesia induction rapid and stable, stable intraoperative circulation, rapid recovery and safe and comfortable, reduce the Incidence of intraoperative awareness, arrhythmia, postoperative delusion, and so on, which is conducive to rapid postoperative recovery and reduce hospitalization costs.

Read the detailed description

Research background: Rapid and steady anesthesia induction, stable intraoperative circulation, rapid recovery, safe and comfortable, and few adverse reactions are the goals of anesthesiologists. Accelerating the surgical turnover and improving the efficiency are the clinical problems that need to be solved. Clinical general anesthesia often adopts static inhalation compound anesthesia to give full play to the advantages of intravenous and inhalation anesthesia and reduce their respective adverse reactions. Remimazolam, as a new ultra-short-acting benzodiazepine sedative, is not widely used in elderly patients, but its rapid onset, short time half-life, less accumulation, little cardiopulmonary inhibition, no injection pain, and can be antagonized by flumazenil, showing an irreplaceable advantage.

Study objective: To observe the efficacy and safety of remimazolam for the induction and maintenance of anesthesia in elderly patients, and to provide a new option for anesthesia management in elderly and critically ill patients.

Study method: This topic adopts a single-center, prospective, randomized, controlled research method, and expects to include 60 elderly subjects with general endotracheal anesthesia for elective surgery.

02

Conditions studied

  • Efficacy and Safety

Keywords

  • remimazolam
  • anesthesia induction
  • continuous anesthesia
03

In context

Lead sponsor

Affiliated Hospital of Nantong University is the lead sponsor of 92 studies on the registry; 53 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
60 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Patients undergoing surgery for clinically diagnosed thyroid tumors
  2. Patients with general anesthesia
  3. Patients requiring endotracheal intubation
  4. American Society of Anesthesia gradeⅡ to grade Ⅲ
  5. age 60-75 years old
  6. body mass index was between 18 and 28
  7. Patients or their family was clear about the study process and volunteered to participate.

Exclusion criteria

Exclusion Criteria:

  1. Patients with known allergy to remimazolam or with previous history of severe allergy and family history
  2. Patients with long-term use of narcotic analgesics, sedatives, or non- steroidal anti-inflammatory drugs
  3. Patients with drug taking, opioid dependence or tolerance
  4. Patients with combined brain injury or intracranial hypertension
  5. Patients with severe abnormal function of the heart, lung, liver, kidney and other major organs
  6. Patients with bradycardia, with a heart rate lower than 55 beats / minute or a high atrioventricular block
  7. Patients with a previous history of allergic disease
  8. Patients with a previous history of mental illness
  9. Patients with a foreseeable difficult airway
  10. The investigator does not consider it appropriate to attend this clinical investigator.
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
92 participants (actual)

Study arms

  • Experimental
    group R

    This group is the experimental group with remimazolam for anesthesia induction and maintenance

    Drug: Remimazolam

  • Active comparator
    group P

    This group is the control group with propofol for anesthesia induction and maintenance

    Drug: Propofol

Interventions

  • DrugRemimazolam

    remimazolam 0.2mg / kg was injected IV during the induction of anesthesia,and remimazolam 0.3-0.5mg / kg / h was administered IV during anesthesia maintenance.

    Also known as: R

  • DrugPropofol

    Propofol 1.5-2mg / kg was injected IV during the induction of anesthesia,and Propofol 2-3mg / kg / h was administered IV during anesthesia maintenance.

    Also known as: P

06

What researchers measure

Primary outcomes

  1. Success rate of induction of anesthesia

    Modified Observer's Assessment of Alertness/Sedation (MOAA/S) score ≤ 1 point within 5 minutes of administration (The rating scale ranges from levels 0 to 5, and lower MOAA / S score indicates deeper depth of sedation, namely a higher scores mean a worse outcome. )

    Time frame: At 5 minutes after the onset of anesthesia induction

Secondary outcomes

  1. Supplement rate of the study drug

    Number of patients requiring remimazolam supplementation / total number of patients in the experimental group

    Time frame: During the operation period

  2. Sedation depth

    the Modified Observer's Assessment of Alertness/Sedation (MOAA/S) score at the different time points (The rating scale ranges from levels 0 to 5, and lower MOAA / S score indicates deeper depth of sedation, namely a higher scores mean a worse outcome. )

    Time frame: At the beginning of induction (T0); bispectral index at 60 (T1); at 1minute after endotracheal intubation (T2); at surgical skin incision (T3), 30 minutes after the start of surgery(T4), at the end of surgery (T5), and 1minute (T6) after extubation

  3. Amount of sedative and analgesic drugs used

    Amount of sedation and analgesics used per unit time during anesthesia maintenance period

    Time frame: During anesthesia maintenance period

  4. Hemodynamic index (1)

    Heart rate

    Time frame: At the beginning of induction (T0); bispectral index at 60 (T1); at 1minute after endotracheal intubation (T2); at surgical skin incision (T3), 30 minutes after the start of surgery(T4), at the end of surgery (T5), and 1minute (T6) after extubation

  5. Hemodynamic index (2)

    mean arterial pressure

    Time frame: At the beginning of induction (T0); bispectral index at 60 (T1); at 1minute after endotracheal intubation (T2); at surgical skin incision (T3), 30 minutes after the start of surgery(T4), at the end of surgery (T5), and 1minute (T6) after extubation

Other outcomes

  1. General data of the patient

    Gender, age, height, weight, current medical history, history of combined diseases and medication allergy, history of hypertension / diabetes (maximum hypertension / blood glucose, type and age of medication, and complications of other organs)

    Time frame: Before the operation

  2. Perioperative adverse events

    Incidence of intraoperative awareness, arrhythmia, postoperative delusion, and so on

    Time frame: up to 24 hours after surgery

  3. Patient satisfaction questionnaire

    The rating scale ranges from levels dissatisfaction, basic satisfaction, satisfaction to very satisfaction, the higher scores mean a better outcome.

    Time frame: up to 24 hours after surgery

  4. Peri-operative-related indicators(1)

    Operation time

    Time frame: up to 6 hours after surgery

  5. Peri-operative-related indicators(2)

    extubation time

    Time frame: up to 6 hours after surgery

  6. Peri-operative-related indicators(3)

    Wake up time

    Time frame: up to 6 hours after surgery

  7. Peri-operative-related indicators(4)

    residence time of Post-anesthesia care unit

    Time frame: up to 12 hours after surgery

07

Study locations

1 site
  • Affiliated Hospital of Affiliated Hospital
    Nantong, Jiangsu 226001, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06690424
Lead sponsor
Affiliated Hospital of Nantong University
Responsible party
Sponsor
First posted
Nov 15, 2024
Start date
Jun 20, 2025
Primary completion
Dec 30, 2025
Completion
Jan 31, 2026
Last update
Apr 6, 2026

Study contacts

Xiao MB Director of scientific research Department, Doctor
principal investigator · Affiliated Hospital of Nantong University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion